Navigation Links
GeoVax Labs Presents New Findings on Potential HIV Vaccine at 2012 Conference on Retroviruses and Opportunistic Infections (CROI)
Date:3/7/2012

ATLANTA, March 7, 2012 /PRNewswire/ -- Harriet L. Robinson, Ph.D., Chief Scientific Officer at GeoVax Labs, Inc. (OTCQB/OTCBB: GOVX), a biotech company specializing in the development of HIV/AIDS vaccines, announced the results of a study suggesting that scientists may be one step closer to a vaccine that protects against multiple exposures to HIV infections. The study results were unveiled by Dr. Robinson during a presentation in Seattle at the 2012 Conference on Retroviruses and Opportunistic Infections (CROI).

Dr. Robinson, working alongside Rama Rao Amara, Ph.D., Associate Professor of Microbiology and Immunology, Yerkes National Primate Research Center, and member of the Emory Vaccine Center, tested a novel vaccine against HIV/AIDS for the ability to protect non-human primates against a series of 36 exposures to simian immunodeficiency virus (SIV) given in three clusters of 12 each over more than 2.5 years. The serial exposures were initiated using the SIVE660 virus that is genetically distinct from the vaccine, followed by exposure to SIV251, the most potent strain of SIV used in non-human primate studies.

The high protective activity of the vaccine is achieved by co-expressing granulocyte-macrophage colony-stimulating factor (GM-CSF) in the DNA vaccine used to prime the vaccine response. GM-CSF is a normal human protein that promotes the initiation of immune responses. By co-expressing GM-CSF and HIV proteins in the DNA vaccine, GM-CSF is present at the site of vaccination where it enhances the ability of the vaccine to elicit blocking antibodies for the virus. Blocking antibodies can stop a virus before it infects cells.

The vaccination regimen consisted of two DNA inoculations at months 0 and 2 to prime the vaccine response and then two booster inoculations at months 4 and 6. The booster vaccine was MVA, a recombinant poxvirus expressing HIV proteins. Six months after the last vaccination, both vaccinated and unvaccinated animals wer
'/>"/>

SOURCE GeoVax Labs, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. GeoVax Labs, Inc. Announces Six Month Financial Results and Provides Operational Update
2. GeoVax Labs, Inc. Information To Be Available Through Standard & Poors Market Access Program
3. GeoVax Presents Data at AIDS Vaccine 2008 Conference
4. GeoVaxs DNA and MVA Vaccines Shipped to HIV Vaccine Trials Network for Use in the Upcoming Phase 2a Trial
5. GeoVax Labs, Inc. Announces Third Quarter 2008 Financial Results and Provides Operational Update
6. GeoVax to Present at the BIO CEO & Investor Conference 2009
7. GeoVax to Webcast Its Presentation at the BIO CEO & Investor 2009 Conference
8. GeoVax Update Provided at the BIO CEO & Investor Conference 2009
9. GeoVax Labs, Inc. Reports Fourth Quarter and Year-End 2008 Financial Results
10. GeoVax Labs, Inc. Announces First Quarter Financial Results
11. GeoVax to Exhibit at the 2009 BIO International Convention
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... CHAPEL HILL, N.C. , Dec. 22, 2014 ... ALNE) today announced that it has signed a ... biotechnology company that has developed and patented a ... and medical diagnostics products that enable rapid on-site ... and alcohol use/abuse and health issues in an ...
(Date:12/22/2014)... The American Journal of Hematology/Oncology, ... and editorials addressing developments and pathways related to ... provocative article exploring the role of follicle-stimulating hormone ... of prostate cancer. , The article references ... that there could be a connection to prostate ...
(Date:12/19/2014)... Tigard, OR and Hershey, PA (PRWEB) December 19, ... (OTC Pink: BJCT), a leading developer and manufacturer ... has entered into an agreement with Immunomic Therapeutics, ... Bioject’s Biojector®-2000 needle-free injection device with its LAMP™ ... receives an option for an exclusive Worldwide license ...
(Date:12/19/2014)... Ill. , Dec. 19, 2014 Naurex ... develop novel drugs for diseases of the central nervous ... president and chief executive officer, will present at the ... Riedel,s presentation will take place at 3:00 p.m. PST ... Francis in San Francisco, Calif. ...
Breaking Biology Technology:ALNE Announces Intention To Acquire BioTechPharma 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 4Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3Naurex to Present at 33rd Annual J.P. Morgan Healthcare Conference 2
... Designation Process and Saves Lives, HARRISBURG, Pa., Aug. ... Web portal that will enable individuals to,sign up as ... driver,s,license or photo ID card is up for renewal ... Web portal, http://www.donatelife-pa.org, will link visitors to ...
... - Despite outcome, CEO Mark McDade to resign ... 20 PDL BioPharma, Inc.,(PDL) (Nasdaq: PDLI ... the company,s chief executive officer (CEO), Mark McDade,found ... breach of,fiduciary duty by McDade to corroborate the ...
... Fisher,Scientific Inc. (NYSE: TMO ) announced today ... and chief executive,officer, are adopting stock- trading programs ... the future sale of company stock. Mr.,Dekkers, who ... August,15-17, 2007, has adopted a plan for the ...
Cached Biology Technology:Web Portal Makes Organ Donation Easy 2PDL BioPharma Announces Internal CEO Investigation Found No Credible Evidence of Improper Personal Conduct or Breach of Fiduciary Duty 2PDL BioPharma Announces Internal CEO Investigation Found No Credible Evidence of Improper Personal Conduct or Breach of Fiduciary Duty 3PDL BioPharma Announces Internal CEO Investigation Found No Credible Evidence of Improper Personal Conduct or Breach of Fiduciary Duty 4Thermo Fisher Scientific Executive Officers Adopting SEC Rule 10b5-1 Trading Programs 2
(Date:12/19/2014)... Research and Markets ( http://www.researchandmarkets.com/research/86ncd6/micro_market ) ... Monitor: North America Perimeter Security Systems Market" report ... The North American perimeter security market ... from 2014 to 2019. Although the U.S. market holds ... is expected to grow at a higher ...
(Date:12/17/2014)... BELVOIR, Va. , Dec. 15, 2014 /PRNewswire-USNewswire/ ... efforts to make it easier to detect and ... chain. Today the agency started performing ... The capability will validate the authenticity of purchased ... chain. The new quality control measures will be ...
(Date:12/17/2014)...  Automation is fundamentally transforming the travel experience ... international borders. Over the past decade, ePassports, biometric ... travelers to self process through border control via ... an increasing number of airports, seaports, and land ... to Maxine Most , Principal at Acuity ...
Breaking Biology News(10 mins):Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 3Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2
... April 2009 A major effort from within ... of an exceptional supplement by the Elsevier journal ... ). The supplement provides extensive studies based on ... niger and Aspergillus nidulans. The publication was enabled ...
... suffer medical complications from hypodermic needles that penetrate too ... MIT engineers and colleagues aims to prevent this from ... which is purely mechanical, is based on concepts borrowed ... needle containing a filament that acts as a guide ...
... down the constituent of olive oil that gives greatest protection ... major antioxidants in olive oil, Portuguese researchers showed that one, ... other part of olive oil. "These findings provide the ... seen in people who have olive oil in their diet," ...
Cached Biology News:MIT: Novel needle could cut medical complications 2
... RNasin Ribonuclease Inhibitors have broad spectrum RNase ... RNases of the neutral type (1). The ... noncovalently binding to RNases in a 1:1 ... of RNasin Ribonuclease Inhibitor to RNase (e.g., ...
... nucleic acids ,The GC-RICH PCR System, ... a proofreading polymerase, powers through templates that ... other polymerases and other blends of polymerases. ... the unique GC-RICH Resolution Solution combine to ...
... Start Taq Monoclonal Antibody ... the onset of thermal ... and primer-dimer formation. When ... the antibody is quickly ...
B-FABP (FL-132)...
Biology Products: